D'Andrea G, Granella F, Cadaldini M, Manzoni G C
Department of Neurology, Este Hospital.
Cephalalgia. 1999 Jan;19(1):64-6. doi: 10.1111/j.1468-2982.1999.1901064.x.
We report a small open pilot study to evaluate the efficacy of lamotrigine (100 mg/day) in the prevention of migraine with aura attacks. We studied 24 patients affected by migraine with aura with a high frequency of attacks. Following a 1-month run-in period, the patients took lamotrigine for 3 months. Mean attack number per month was reduced from 6.1 +/- 4.1 during the run-in period to 0.7 +/- 1.3 at the 3rd month of treatment (p < 0.0001). In 13 out of 21 patients who completed the study, the attacks were completely abolished at the 3rd month of treatment, while only one patient was completely unresponsive to the drug. Lamotrigine seems worthy of a controlled trial as prophylaxis of a migraine with aura.
我们报告一项小型开放性初步研究，以评估拉莫三嗪（100毫克/天）预防伴有先兆偏头痛发作的疗效。我们研究了24例伴有先兆偏头痛且发作频率高的患者。在1个月的导入期后，患者服用拉莫三嗪3个月。每月平均发作次数从导入期的6.1±4.1次减少至治疗第3个月时的0.7±1.3次（p<0.0001）。在完成研究的21例患者中，有13例在治疗第3个月时发作完全消失，而只有1例患者对该药完全无反应。拉莫三嗪作为伴有先兆偏头痛的预防性药物似乎值得进行对照试验。
